DiaMedica Therapeutics Inc. (DMAC) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

DiaMedica Therapeutics Inc. (DMAC) Healthcare & Pipeline Overview

DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company focusing on the development of DM199, a recombinant human tissue kallikrein-1 protein, for treating neurological and kidney diseases, specifically chronic kidney disease and acute ischemic stroke. The company is currently conducting Phase 2 and Phase 2/3 trials.

What Is the Investment Thesis for DMAC?

DiaMedica Therapeutics Inc. presents a high-risk, high-reward investment opportunity centered on the clinical development of DM199. The primary value driver is the successful completion of the Phase 2 REDUX trial for chronic kidney disease and the Phase 2/3 REMEDY2 trials for acute ischemic stroke. Positive data from these trials could lead to significant stock appreciation. Key catalysts include interim data readouts from the ongoing trials and potential partnerships for late-stage development and commercialization. However, the company faces significant risks, including clinical trial failures, regulatory hurdles, and the need for additional capital to fund operations. The company's market capitalization is $349M, reflecting the speculative nature of its pipeline.

Based on FMP financials and quantitative analysis

DMAC Key Highlights

DM199 is in Phase 2 REDUX trial for chronic kidney disease, targeting a significant unmet need in diabetic patients.

• DM199 is in Phase 2/3 REMEDY2 trials for acute ischemic stroke, a large market with limited treatment options.
• The company is developing DM300, a pre-clinical stage asset targeting inflammatory diseases, offering potential future growth.
• DiaMedica Therapeutics Inc. has a market capitalization of $349M, reflecting its stage of development.
• The company is led by CEO Dietrich John Pauls, who manages a team of 27 employees.

Who Are DMAC's Competitors?

DMAC is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are DMAC's Key Strengths?

Novel therapeutic approach targeting KLK1.

• Clinical-stage pipeline with DM199 in Phase 2 and Phase 2/3 trials.
• Experienced management team.
• Potential for first-in-class treatment options.

What Are DMAC's Weaknesses?

Limited financial resources.

• High reliance on the success of DM199.
• Small company size with limited infrastructure.
• No current revenue stream.

What Could Drive DMAC Stock Higher?

Interim data readout from the Phase 2 REDUX trial for chronic kidney disease.

• Data readout from the Phase 2/3 REMEDY2 trials for acute ischemic stroke.
• Potential partnerships for late-stage development and commercialization.
• Continued enrollment in the Phase 2 REDUX and Phase 2/3 REMEDY2 trials.

What Are the Key Risks for DMAC?

Negative return on equity (-77.1%) — the business is not currently generating profit on shareholder capital.

• Inconsistent delivery — missed Wall Street EPS estimates in 3 of the last 8 reported quarters.
• Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures for DM199.
• Regulatory hurdles and delays.
• Competition from other pharmaceutical companies.
• Need for additional capital to fund operations.
• Manufacturing and supply chain challenges.

What Are the Growth Opportunities for DMAC?

• Successful Completion of Phase 2 REDUX Trial: The successful completion of the Phase 2 REDUX trial for DM199 in chronic kidney disease (CKD) represents a significant growth opportunity. The CKD market is substantial, with a global market size estimated at billions of dollars. Positive trial results could lead to accelerated development and potential commercialization, providing a first-in-class treatment option for patients with diabetic kidney disease. The timeline for this opportunity is dependent on the trial's progress and data readout, expected within the next 12-18 months.
• Advancement of Phase 2/3 REMEDY2 Trials for Acute Ischemic Stroke: The advancement of DM199 through the Phase 2/3 REMEDY2 trials for acute ischemic stroke (AIS) is another key growth driver. The AIS market is characterized by a high unmet need for effective therapies. Positive results from the REMEDY2 trials could position DM199 as a valuable treatment option for stroke patients. The timeline for this opportunity is contingent on the trial's progress and data readout, anticipated within the next 24-36 months.
• Development of DM300 for Inflammatory Diseases: The development of DM300, currently in the pre-clinical stage, for the treatment of inflammatory diseases represents a longer-term growth opportunity. The inflammatory disease market is broad and includes conditions such as rheumatoid arthritis and inflammatory bowel disease. Successful pre-clinical development and subsequent clinical trials could lead to a new therapeutic option for patients with inflammatory disorders. The timeline for this opportunity extends beyond the next 3-5 years.
• Strategic Partnerships for Late-Stage Development and Commercialization: DiaMedica can pursue strategic partnerships with larger pharmaceutical companies for late-stage development and commercialization of DM199 and DM300. These partnerships could provide financial resources, expertise, and infrastructure to accelerate the development and market access of DiaMedica's drug candidates. The timeline for this opportunity is ongoing, as DiaMedica actively seeks potential partners.
• Expansion into New Therapeutic Areas: DiaMedica can leverage its expertise in kallikrein-kinin system biology to expand its pipeline into new therapeutic areas beyond neurological and kidney diseases. This could involve exploring the potential of DM199 or new drug candidates in other indications where KLK1 plays a role. The timeline for this opportunity is longer-term, requiring further research and development efforts.

What Are DMAC's Competitive Advantages?

• Proprietary knowledge of kallikrein-kinin system biology.
• Patent protection for DM199 and DM300.
• Clinical data supporting the efficacy and safety of DM199.
• First-mover advantage in targeting KLK1 for neurological and kidney diseases.

What Does DMAC Do?

DiaMedica Therapeutics Inc., founded in 2000 and headquartered in Minneapolis, Minnesota, is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel treatments for neurological and kidney diseases. The company's primary focus is on advancing its lead drug candidate, DM199, a recombinant human tissue kallikrein-1 (rhKLK1) protein. DM199 is currently undergoing clinical trials for the treatment of patients with moderate to severe chronic kidney disease (CKD) caused by Type I or Type II diabetes (REDUX trial, Phase 2) and for patients with acute ischemic stroke (AIS) in the REMEDY2 trials (Phase 2/3). DiaMedica's approach centers around harnessing the therapeutic potential of KLK1, a naturally occurring serine protease, to improve blood flow, reduce inflammation, and promote neuroprotection. Beyond DM199, DiaMedica is also developing DM300, a pre-clinical stage asset targeting inflammatory diseases. The company was initially incorporated as DiaMedica Inc. and rebranded to DiaMedica Therapeutics Inc. in December 2016, reflecting its intensified focus on therapeutic development. With a team of 27 employees, DiaMedica is striving to address unmet medical needs in areas with limited treatment options.

What Products and Services Does DMAC Offer?

• Develops treatments for neurological diseases.
• Develops treatments for kidney diseases.
• Focuses on recombinant human tissue kallikrein-1 protein (DM199).
• Conducts Phase 2 trials for chronic kidney disease (REDUX trial).
• Conducts Phase 2/3 trials for acute ischemic stroke (REMEDY2 trials).
• Develops DM300 for inflammatory diseases (pre-clinical stage).

How Does DMAC Make Money?

• Focuses on research and development of novel therapeutics.
• Out-licenses or partners for late-stage development and commercialization.
• Generates revenue through potential future drug sales or licensing agreements.

What Industry Does DMAC Operate In?

DiaMedica Therapeutics Inc. operates within the biotechnology industry, a sector characterized by high innovation, long development timelines, and significant regulatory oversight. The market for neurological and kidney disease treatments is substantial and growing, driven by aging populations and increasing prevalence of chronic conditions like diabetes and stroke. Competition is intense, with numerous companies developing novel therapies. DiaMedica's success depends on its ability to differentiate DM199 and DM300 through clinical efficacy and safety. The biotechnology industry is projected to continue its growth trajectory, fueled by advancements in genomics, personalized medicine, and novel drug delivery systems.

Who Are DMAC's Key Customers?

• Patients with chronic kidney disease.
• Patients with acute ischemic stroke.
• Potential future patients with inflammatory diseases.

DiaMedica Therapeutics Inc. (DMAC) Valuation Context

Valued at $349M, DMAC is classified as a small-cap stock. Relative to its peer group, DMAC's quantitative score of 54/100 is below the peer average of 78/100.

DMAC Revenue & Earnings Trend

In Q2 FY2026, DMAC generated $0 in top-line revenue. The company recorded a net loss of $10.1M, with diluted EPS of $-0.19. Quarter-over-quarter revenue has been mixed, typical for a small-cap company operating in Healthcare. Across the four most recent quarters, DMAC averaged $-0.18 in diluted EPS.

Company Profile

DiaMedica Therapeutics Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Minneapolis, US. The company is led by CEO Dietrich John Pauls. DMAC has traded publicly since 2012.

Return on equity for DiaMedica Therapeutics Inc. stands at -77.1%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -66.1%, showing how much profit it generates from its asset base. Its free cash flow yield is -10.6%, a gauge of the cash the business throws off relative to its market value. A current ratio of 9.11 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -12.0%, the inverse of the P/E and a quick read on earnings relative to price.

DiaMedica Therapeutics Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 24.23 places it in the safe zone, indicating low near-term bankruptcy risk.

DiaMedica Therapeutics Inc. has missed Wall Street's EPS estimate in 3 of its last 8 reported quarters — a recurring pattern of falling short of estimates. Reported results have landed about 3.2% below estimates on average.

The most recent 12 insider filings for DiaMedica Therapeutics Inc. break down as 1 sales and 11 purchases. On net that is roughly 954K shares acquired (about $6.6M) — insiders putting money in tends to read as conviction.

DMAC Financials

DMAC Latest News

DMAC Analyst Consensus

DMAC MoonshotScore

DiaMedica Therapeutics Inc. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources